Abstract
Objective: To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry. Methods: This retrospective analysis was based on data from patients with HAE type I/II who received healthcare professional-administered or self-administered icatibant to treat laryngeal attacks between September 2008 and May 2013. Results: Twenty centers in seven countries contributed data. Overall, 42 patients with HAE experienced 67 icatibant-treated laryngeal attacks. Icatibant was self-administered for 62.3% of attacks (healthcare professional-administered, 37.7%). One icatibant injection was used for 87.9% of attacks, with rescue or concomitant medication used for 9.0%. The median time to treatment was 2.0 h (n=31 attacks) and the median time to resolution was 6.0 h (n=35 attacks). Conclusions This analysis describes successful use of icatibant for the treatment of laryngeal HAE attacks in a real-world setting.
| Original language | English |
|---|---|
| Pages (from-to) | 224-227 |
| Number of pages | 4 |
| Journal | European Journal of Emergency Medicine |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2016 |
Keywords
- C1-inhibitor deficiency
- acquired angioedema
- hereditary angioedema
- icatibant
- laryngeal edema
- observational study
- therapy